浩欧博发布2025年度业绩快报，盈利0.234亿元

Core Viewpoint - The company, Haooubo, is set to release its 2025 annual report, with a significant decline in net profit of 36.37% year-on-year, amounting to 0.234 billion yuan [1]. Group 1: Operating Performance - During the reporting period, the company achieved operating revenue of 398.40 million yuan, a decrease of 0.98% compared to the same period last year [2]. - The operating profit was 26.66 million yuan, down 35.57% year-on-year [2]. - The net profit attributable to the parent company was 23.42 million yuan, reflecting a decline of 36.37% year-on-year [2]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 14.94 million yuan, a decrease of 58.36% compared to the previous year [2]. Group 2: Financial Condition - At the end of the reporting period, the company had total assets of 931.80 million yuan, a decrease of 9.78% from the beginning of the period [3]. - The equity attributable to the parent company was 820.39 million yuan, which represents a growth of 1.02% from the beginning of the period [3]. Group 3: Factors Affecting Performance - The overall sales scale experienced a slight decline due to the impact of the macro market environment and related policy adjustments, affecting revenue and net profit [4][5]. - Increased depreciation expenses due to the expansion of automated instrument deployment and the commissioning of a new building from fundraising projects contributed to a rise in overall costs [4][5]. - The company increased marketing investments for its desensitization drug, Otuok, along with rising clinical registration costs [4][5]. - The difference in growth rates of net profit before and after deducting non-recurring gains and losses was primarily due to gains from the disposal of an old factory in 2025 [5]. Group 4: Business Overview - Haooubo (688656) is engaged in the research, development, production, and sales of in vitro diagnostic reagents [6].